Immunocore Holdings plc (IMCR): Depreciation & Amortization

Annual figures by period end, from SEC filings.

$3.10M
Year ended 2025-12-31
-16.4%
3-year compound annual growth
$7.60M2021-12-31: $7.60M2022-12-31: $5.30M2023-12-31: $4.10M2024-12-31: $4.20M2025-12-31: $3.10M$3.10M
2021-12-31 Depreciation & Amortization (USD) 2025-12-31
Period endedDepreciation & AmortizationChange YoYSource filing
2025-12-31$3.10M-26.2%2026-02-25, From 2025-01-01
2024-12-31$4.20M+2.4%2026-02-25, From 2024-01-01
2023-12-31$4.10M-22.6%2026-02-25, From 2023-01-01
2022-12-31$5.30M-30.3%2025-02-26, From 2022-01-01
2021-12-31$7.60Mn/a2024-02-28, From 2021-01-01

Depreciation & Amortization at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedDepreciation & AmortizationChange YoY
Immunocore Holdings plc (IMCR)2025-12-31$3.10M-26.2%
Twist Bioscience Corp (TWST)2025-09-30$24.85M-20.9%
ADMA Biologics, Inc. (ADMA)2025-12-31$8.10M+0.6%
Adaptive Biotechnologies Corp (ADPT)2025-12-31$16.00M-8.3%
Vericel Corp (VCEL)2025-12-31$11.54M+109.7%
Iovance Biotherapeutics, Inc. (IOVA)2025-12-31$35.94M-4.4%
Vaxart, Inc. (VXRT)2025-12-31$8.58M-3.1%
Repligen Corp (RGEN)2025-12-31$78.75M+13.0%
BioCryst Pharmaceuticals Inc (BCRX)2025-12-31$1.39M+11.5%

Compare IMCR, TWST, ADMA, ADPT side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗